Thus, our data illustrate an essential function for RRP9 to promote gemcitabine resistance, and indicate that targeting RRP9 through AKT could propose a new therapeutic strategy to sensitize PC cells to gemcitabine. This evidence concerns the gene AKT1 and pachyonychia congenita.